MSAB is a selective inhibitor of Wnt/β-catenin signaling that binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB shows potent anti-tumor effects.
MSAB is a selective inhibitor of Wnt/β-catenin signaling that binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB shows potent anti-tumor effects.
MSAB impedes RAW264.7 cells and human PMBCs differentiating into OCs. MSAB decreases the expression of β‐catenin in RAW264.7 and ARP1 WT cells.[2]
MSAB (10-20 mg/kg; i.p. daily for 2 weeks) inhibits tumor growth of Wnt-dependent cancer cells in xenograft mice and MMTV-Wnt1 transgenic mice.[3]
[1] So-Young Hwang, et al. Cell Rep. 2016 Jun 28;16(1):28-36. [2] Zhang Y, et al. Clin Transl Med. 2022 Feb;12(2):e684.
动态评分
0.0